Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis

Infliximab, an inhibitor of TNF-α, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline serum TNF-α could be considered as a key indicator for optimal dosing of infliximab for RA treatment to achieve the clinical response and its sus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Contemp Clin Trials Commun
Main Authors: Oba, Koji, Horie, Nao, Sato, Norihiro, Saito, Kazuyoshi, Takeuchi, Tsutomu, Mimori, Tsuneyo, Miyasaka, Nobuyuki, Koike, Takao, Tanaka, Yoshiya
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5898537/
https://ncbi.nlm.nih.gov/pubmed/29696196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2017.08.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados